Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	2.08B
Revenue (ttm)	n/a
Net Income (ttm)	-240.63M
Shares Out	84.99M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412,545
Open	24.88
Previous Close	24.63
Day's Range	24.43 - 25.07
52-Week Range	11.22 - 25.34
Beta	0.94
Analysts	Strong Buy
Price Target	34.56 (+41.12%)
Earnings Date	Aug 1, 2024

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX

Analyst Forecast

According to 9 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $34.56, which is an increase of 41.12% from the latest price.

Price Target

$34.56

(41.12% upside)

Analyst Consensus: Strong Buy